I'm not saying which are overhyped I'm just saying why don't overseas Big Pharma swoop on our biotechs with acquisitions or big licensing deals?
I'm not a big believer of the usual arguments - tight registries, waiting for proof of concept or later validation, etc.
If somebody has super hot tech or drug candidates, the likes of Gilead would think nothing of throwing a few billion at it, regardless what stage of development. They wouldn't think twice. They'd just take it.
Stuart Roberts likes to talk about examples of mega deals, but cant seem to use many ozzie companies as examples.
